Linagliptine Eg (Eurogenerics) Sa (Linagliptin)

Linagliptin inhibits the enzyme dipeptidyl peptidase‑4 (DPP‑4), preventing the breakdown of the incretin hormones GLP‑1 and GIP. Higher levels of these hormones increase insulin secretion and decrease glucagon release in a glucose‑dependent manner, leading to lower fasting and post‑prandial blood glucose concentrations.

The dosage of linagliptin is individualized by the prescribing clinician based on the patient’s overall treatment plan, renal and hepatic status, and response to therapy. It is typically administered once daily as an oral tablet, but the exact strength and regimen are determined by the healthcare professional.

Safety of linagliptin during pregnancy and lactation has not been established. It should be avoided unless the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternative treatment options with their physician.

To place an order, submit an enquiry on the Linagliptine Eg product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin shares the same class mechanism as other DPP‑4 inhibitors such as sitagliptin or saxagliptin, but it is distinguished by its primarily non‑renal elimination, allowing use without dose adjustment in patients with renal impairment. Efficacy and safety profiles are comparable, though individual tolerability may vary.

Linagliptine Eg tablets should be stored at ambient temperature below 25 °C, protected from moisture and kept in the original packaging until use. Avoid exposure to direct sunlight or excessive humidity, and keep the product out of reach of children.

The medication is supplied as oral tablets that are swallowed whole with water. It is usually taken once daily, with or without food, as directed by the prescribing clinician. Patients should follow the specific instructions provided on the prescription label.

Serious adverse events, although rare, include acute pancreatitis, severe allergic reactions such as angioedema or anaphylaxis, and serious skin disorders like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience persistent abdominal pain, swelling of the face or throat, or widespread rash.

Linagliptine Eg is contraindicated in individuals with known hypersensitivity to linagliptin or any of the tablet excipients. Caution is also advised for patients with severe hepatic impairment, a history of pancreatitis, or those who are pregnant or breastfeeding unless the benefits clearly outweigh the risks.